Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

Investing.com -- Amneal Pharmaceuticals (NASDAQ:AMRX) stock jumped 5.9%, LegalZoom.com (NASDAQ:LZ) rose 5.2%, and Dutch Bros (NYSE:BROS) gained 2.9% in after-hours trading Tuesday after S&P Dow Jones Indices announced these companies would be added to its indices.

S&P Dow Jones Indices revealed multiple changes to its S&P MidCap 400 and S&P SmallCap 600 indices, triggering price movements in several affected stocks. The changes are scheduled to take effect in late January and early February 2026.

TTM Technologies (NASDAQ:TTMI), which will move from the SmallCap 600 to the MidCap 400, saw its shares increase 0.4%. American Healthcare REIT (NYSE:AHR) gained 2.9% on news it would join the MidCap 400, while Apellis Pharmaceuticals (NASDAQ:APLS) rose 2% as it’s set to enter the SmallCap 600.

The index changes are primarily due to pending acquisitions. S&P SmallCap 600 constituent SM Energy (NYSE:SM) is acquiring Civitas Resources (NYSE:CIVI), while Rayonier (NYSE:RYN) is purchasing PotlatchDeltic (NASDAQ:PCH). Fifth Third Bancorp (NASDAQ:FITB) is in the process of acquiring Comerica (NYSE:CMA), and Huntington Bancshares (NASDAQ:HBAN) is buying Cadence Bank (NYSE:CADE).

Additionally, LegalZoom.com will replace Elme Communities (NYSE:ELME) in the SmallCap 600, as Elme has announced ongoing liquidation activities.

The first round of changes will take effect prior to market open on January 30, 2026, with TTM Technologies replacing Civitas Resources in the MidCap 400 and Amneal Pharmaceuticals taking TTM’s spot in the SmallCap 600. The remaining changes will be implemented before trading begins on February 2, 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Amneal Pharmaceuticals Inc Class A (NASDAQ:AMRX) stock rose 2% in after-hours trading on Monday after the company announced FDA approval for two biosimilar drugs, expanding its portfolio in the growing biosimilars market.

The U.S. Food and Drug Administration approved Amneal’s Biologics Licensing Applications for Boncresa (denosumab-mobz), a biosimilar referencing Prolia, and Oziltus (denosumab-mobz), a biosimilar referencing XGEVA. Both original drugs are used to treat bone-related conditions in oncology and osteoporosis patients.

Under Amneal’s partnership with mAbxience, a Fresenius Kabi majority-owned group, mAbxience handles development and manufacturing while Amneal maintains exclusive U.S. commercialization rights for the products.

"Biosimilars are the next wave of affordable medicines in the U.S., expanding access to life-changing biologics for millions of patients," said Chirag and Chintu Patel, Co-Chief Executive Officers of Amneal. "With the addition of two denosumab biosimilars, Amneal now has five commercial biosimilars, strengthening our position in this rapidly growing category."

The approvals represent significant progress toward Amneal’s goal of commercializing six biosimilars across eight presentations by 2027. According to IQVIA data, U.S. annual sales for Prolia and XGEVA for the 12 months ended October 2025 were approximately $5.3 billion, indicating the market potential for these newly approved biosimilars.

Both medications must be administered by healthcare providers and come with warnings about maintaining proper serum calcium levels. Prolia carries a Boxed Warning regarding severe hypocalcemia risk in patients with advanced chronic kidney disease.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Amneal Pharmaceuticals Inc Class A (NASDAQ:AMRX) stock rose 2.8% in after-hours trading Tuesday following the FDA approval of the company’s epinephrine injection USP, expanding its injectable medicine portfolio.

The newly approved treatment comes in both single-dose vials (1 mg/mL, 1 mL) and multi-dose vials (1 mg/mL, 30 mL) formats. Epinephrine is widely used in emergency and acute care settings for treating severe allergic reactions and managing hypotension in septic shock patients.

"Epinephrine is one of the most important and widely used emergency medicines in healthcare," said Arash Dabestani, Senior Vice President, Institutional at Amneal. "By bringing both single- and multi-dose vial presentations to the institutional market, we are helping expand reliable and affordable access for hospitals and clinical providers."

The approval strengthens Amneal’s position in the injectable medications market, particularly for critical care products used in hospital settings. According to IQVIA data cited by the company, U.S. annual sales for epinephrine injection single- and multi-dose vials reached approximately $118 million for the 12 months ended October 2025.

Epinephrine injection is indicated for emergency treatment of allergic reactions including anaphylaxis from insect stings, food allergies, drug reactions, and other allergens. It is also used to increase blood pressure in adult patients with hypotension related to septic shock.

The company noted that common adverse reactions may include anxiety, tremor, dizziness, sweating, palpitations, nausea, headache, and respiratory difficulties, with higher risk in patients with heart disease, hypertension, or hyperthyroidism.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.